Acute Lymphoblastic Leukemia (ALL) — Deal Benchmarks & Valuation
Market Analysis
Acute Lymphoblastic Leukemia (ALL) is one of the most actively transacted indications in oncology licensing. Phase 1 deals for acute lymphoblastic leukemia (all) carry a median total deal value of $1.0B, with upfront payments ranging from $48M to $158M. The recommended deal structure allocates approximately 10% to upfront payments and 90% to milestones.
Milestone structures for acute lymphoblastic leukemia (all) deals allocate $362M to development milestones, $317M to regulatory milestones, and $227M to commercial milestones. Royalty rates range from 8.9% to 15.6% at the base tier, with tiered escalation reaching 12.9%-19.6% on peak sales.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for acute lymphoblastic leukemia (all) licensing?
What royalty rates are standard for acute lymphoblastic leukemia (all) deals?
How are acute lymphoblastic leukemia (all) deal milestones structured?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.